Secured $76.8 Million Verdict on Behalf of Health Insurers in Direct Action Alleging Unlawful Monopolization of Prescription Drugs

August 29, 2017

In re: Lorazepam & Clorazepate Antitrust Litigation, 99-mc-00276 (D.D.C.)

Robins Kaplan secured a $76.8 million jury verdict on behalf of three health insurers that allegedly overpaid for prescription drugs because of a branded manufacturer’s anticompetitive exclusion of generic competition through the restriction of the generics’ supply of active pharmaceutical ingredients.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.
Disclaimer

Related Practices

Antitrust and Trade Regulation Business Litigation Direct Actions and Opt-Out Practice

Similar Results

Secured Over $1.1 Billion Against BMO Harris Bank in Petters Fraud Litigation Related to One of the Biggest Ponzi Schemes in U.S. History
Business Litigation Financial Markets Litigation Corporate Finance and Securities
Achieved Partial Summary Judgment Win in Semiconductor Device Patent Infringement Case, Resulting in Settlement
Business Litigation Intellectual Property and Technology Litigation Patent Litigation
Achieved Extraordinary $5.5 Billion Settlement in Interchange Fee and Merchant Discount Litigation
Antitrust and Trade Regulation Business Litigation Class Action Litigation
Secured $28 Million Settlement in Alleged Breach of Fiduciary Duties Litigation Against Former Officers and Directors of For-profit College
Business Litigation Financial Markets Litigation
Reached Global, Cost-of-Defense Settlements for Norwegian Salmon Distributor and Producer in Nationwide Antitrust Class Action
Antitrust and Trade Regulation Business Litigation Class Action Litigation
Reached Settlements in Excess of $118 Million in Disposable Contact Lens Antitrust Litigation
Antitrust and Trade Regulation Business Litigation Class Action Litigation
Reached Settlement for Industry Leader in Mortgage Quality Control Alleging that Joint Developer Violated a Non-Compete Provision
Business Litigation Software Litigation Attorneys
Reached Settlement in Antitrust Class Action Relating to Precious Metals Futures Contracts Trading
Antitrust and Trade Regulation Business Litigation Class Action Litigation
Obtained Dismissal with Prejudice of Putative Nationwide False Advertising Class Action for Global Food Manufacturer of Red Baron Pizza
Business Litigation Class Action Litigation
Reached Settlement Worth Up to $28 Million Against Martin Shkreli and His Former Companies for Alleged Monopolization of Life-Saving Drug Daraprim
Antitrust and Trade Regulation Business Litigation Class Action Litigation Health Care Litigation
Resolved Putative Nationwide False Advertising Class Action on Behalf of Genuine Parts Company
Business Litigation Class Action Litigation
Reached Amicable Settlement for Multinational Materials Technology Company in Cross-Border Trade Secret and Breach of Contract Dispute
Business Litigation Intellectual Property and Technology Litigation Trade Secret Litigation
Resolved Putative Nationwide False Advertising Class Action on Behalf of Global Food Manufacturer of Red Baron Pizza
Business Litigation Class Action Litigation
$19.5 Million Settlement Secured for Indirect Buyers in Interior Molded Doors Antitrust Litigation
Antitrust and Trade Regulation Business Litigation Class Action Litigation
Defended Chinese Pharma Co. and CEO of NJ-Based Pharma Co., Successfully Settling Shareholder Derivative Case Alleging Trade Secret Misappropriation
Intellectual Property and Technology Litigation Business Litigation Trade Secret Litigation
Back to Top